ADC/mAb
Trastuzumab Rezetecan (HER2 ADC)
HER2 ADC
Investigational. This is an investigational compound and is not approved for marketing. Material and development services are offered only to qualified entities for research and pharmaceutical development, subject to applicable law.
Trastuzumab rezetecan is an investigational HER2-directed antibody-drug conjugate in clinical development. BOOKPHARM offers it for out-licensing and business development; it is investigational and not approved for marketing.
Supply offerings
| Business line | Business model | Regulatory status |
|---|---|---|
| FDFADC/mAb | License-out | Clinical study I/II |
Supplied for pharmaceutical manufacturing and R&D by licensed and qualified entities. Not for human use as supplied. Availability is subject to regulatory approval in the buyer's jurisdiction.